Dimerix: Notice of Annual General Meeting/Proxy Form
Filed with ASX · · 30 pages · English
In the deck
Story so far
Earlier from Dimerix
- DMX-200 tablet manufacture and human study timeline
- Positive Results from Phase 2a Trial of DMX-200
- Research Validates Relevance of DMX Receptor-HIT Technology
- Investor Update
- Receipt of $420k Research & Development Tax Refund
Later from Dimerix
- Dimerix Receives $545k R&D Tax Refund
- Ethics Committee Approval for Pharmacokinetic Trial
- Dimerix Phase 2a Subgroup Analysis Results
- Suspension from Official Quotation
- Entitlement Offer to raise $5.5 million
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix